Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yukiya Kurahashi

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Infection|July 13, 2022
Acute metatarsal osteomyelitis simulating cellulitisYukiya Kurahashi, Yusuke Ito
The Lancet. Infectious Diseases|June 25, 2022
Mediastinitis associated with a subcutaneous abscess in the chest of a toddlerOsamu Matsumura, Shogo Otake, Yukiya Kurahashi
Journal of Public Health (Oxford, England)|May 16, 2021
Association of undernutrition with dengue, malaria and acute diarrhea among children in a Thai-Myanmar borderYukiya Kurahashi, Weerawan Hattasingh, Supawat Chatchen, et al.
JAMA Network Open|May 9, 2022
Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 VaccineKoichi Furukawa, Lidya Handayani Tjan, Yukiya Kurahashi, et al.
The Journal of Infectious Diseases|April 28, 2022
Induction of High Neutralizing Activity Against Both Omicron BA.2 and Omicron BA.1 by Coronavirus Disease 2019 Messenger RNA Booster VaccinationLidya Handayani Tjan, Koichi Furukawa, Yukiya Kurahashi, et al.
The Journal of Infectious Diseases|September 26, 2022
The Number of Coronavirus Disease 2019 Vaccine Doses and Severe Clinical Outcomes in Older Patients Infected With a Severe Acute Respiratory Syndrome Coronavirus 2 Omicron VariantKoichi Furukawa, Yukiya Kurahashi, Hanako Ishimaru, et al.
Journal of Infection and Public Health|May 17, 2023
Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly populationSilvia Sutandhio, Koichi Furukawa, Yukiya Kurahashi, et al.
Open Forum Infectious Diseases|October 11, 2021
Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in JapanKoichi Furukawa, Lidya Handayani Tjan, Silvia Sutandhio, et al.
The Journal of Infectious Diseases|May 5, 2022
Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA VaccinationYukiya Kurahashi, Koichi Furukawa, Silvia Sutandhio, et al.
Frontiers in Immunology|March 14, 2022
Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After InfectionsYukiya Kurahashi, Silvia Sutandhio, Koichi Furukawa, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Infection|July 13, 2022
Acute metatarsal osteomyelitis simulating cellulitisYukiya Kurahashi, Yusuke Ito
The Lancet. Infectious Diseases|June 25, 2022
Mediastinitis associated with a subcutaneous abscess in the chest of a toddlerOsamu Matsumura, Shogo Otake, Yukiya Kurahashi
Journal of Public Health (Oxford, England)|May 16, 2021
Association of undernutrition with dengue, malaria and acute diarrhea among children in a Thai-Myanmar borderYukiya Kurahashi, Weerawan Hattasingh, Supawat Chatchen, et al.
JAMA Network Open|May 9, 2022
Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 VaccineKoichi Furukawa, Lidya Handayani Tjan, Yukiya Kurahashi, et al.
The Journal of Infectious Diseases|April 28, 2022
Induction of High Neutralizing Activity Against Both Omicron BA.2 and Omicron BA.1 by Coronavirus Disease 2019 Messenger RNA Booster VaccinationLidya Handayani Tjan, Koichi Furukawa, Yukiya Kurahashi, et al.
The Journal of Infectious Diseases|September 26, 2022
The Number of Coronavirus Disease 2019 Vaccine Doses and Severe Clinical Outcomes in Older Patients Infected With a Severe Acute Respiratory Syndrome Coronavirus 2 Omicron VariantKoichi Furukawa, Yukiya Kurahashi, Hanako Ishimaru, et al.
Journal of Infection and Public Health|May 17, 2023
Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly populationSilvia Sutandhio, Koichi Furukawa, Yukiya Kurahashi, et al.
Open Forum Infectious Diseases|October 11, 2021
Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in JapanKoichi Furukawa, Lidya Handayani Tjan, Silvia Sutandhio, et al.
The Journal of Infectious Diseases|May 5, 2022
Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA VaccinationYukiya Kurahashi, Koichi Furukawa, Silvia Sutandhio, et al.
Frontiers in Immunology|March 14, 2022
Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After InfectionsYukiya Kurahashi, Silvia Sutandhio, Koichi Furukawa, et al.
Pageof 2